Multiple Sclerosis - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 922
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MC2C30F5A70EN
Leaflet:

Download PDF Leaflet

Multiple Sclerosis - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H2 2015’, provides an overview of the Multiple Sclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Multiple Sclerosis Overview
Therapeutics Development
Multiple Sclerosis - Therapeutics under Development by Companies
Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes
Multiple Sclerosis - Pipeline Products Glance
Multiple Sclerosis - Products under Development by Companies
Multiple Sclerosis - Products under Investigation by Universities/Institutes
Multiple Sclerosis - Companies Involved in Therapeutics Development
Multiple Sclerosis - Therapeutics Assessment
Drug Profiles
Multiple Sclerosis - Recent Pipeline Updates
Multiple Sclerosis - Dormant Projects
Multiple Sclerosis - Discontinued Products
Multiple Sclerosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Multiple Sclerosis, H2 2015
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2015
Multiple Sclerosis - Pipeline by 4SC AG, H2 2015
Multiple Sclerosis - Pipeline by AB Science SA, H2 2015
Multiple Sclerosis - Pipeline by AbbVie Inc., H2 2015
Multiple Sclerosis - Pipeline by Ablynx NV, H2 2015
Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H2 2015
Multiple Sclerosis - Pipeline by Actelion Ltd, H2 2015
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2015
Multiple Sclerosis - Pipeline by Aegera Therapeutics Inc., H2 2015
Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H2 2015
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2015
Multiple Sclerosis - Pipeline by AiCuris GmbH & Co. KG, H2 2015
Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2015
Multiple Sclerosis - Pipeline by Allozyne, Inc., H2 2015
Multiple Sclerosis - Pipeline by Amarna Therapeutics B.V., H2 2015
Multiple Sclerosis - Pipeline by Antipodean Pharmaceuticals, Inc., H2 2015
Multiple Sclerosis - Pipeline by Antisense Therapeutics Limited, H2 2015
Multiple Sclerosis - Pipeline by Antitope Limited, H2 2015
Multiple Sclerosis - Pipeline by Aphios Corporation, H2 2015
Multiple Sclerosis - Pipeline by Apitope International NV, H2 2015
Multiple Sclerosis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H2 2015
Multiple Sclerosis - Pipeline by Array BioPharma Inc., H2 2015
Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics, Inc., H2 2015
Multiple Sclerosis - Pipeline by Athersys, Inc., H2 2015
Multiple Sclerosis - Pipeline by Axxam SpA, H2 2015
Multiple Sclerosis - Pipeline by Baliopharm AG, H2 2015
Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Multiple Sclerosis - Pipeline by BIOCAD, H2 2015
Multiple Sclerosis - Pipeline by Biocon Limited, H2 2015
Multiple Sclerosis - Pipeline by Biogen, Inc., H2 2015
Multiple Sclerosis - Pipeline by Biogenomics Limited, H2 2015
Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H2 2015
Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2015
Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H2 2015
Multiple Sclerosis - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Multiple Sclerosis - Pipeline by Bionovis SA, H2 2015
Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H2 2015
Multiple Sclerosis - Pipeline by Biovista Inc., H2 2015
Multiple Sclerosis - Pipeline by Bird Rock Bio, Inc., H2 2015
Multiple Sclerosis - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H2 2015
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015
Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Multiple Sclerosis - Pipeline by C4X Discovery Limited, H2 2015
Multiple Sclerosis - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc., H2 2015
Multiple Sclerosis - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015
Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H2 2015
Multiple Sclerosis - Pipeline by Cell2B S.A. , H2 2015
Multiple Sclerosis - Pipeline by Cellceutix Corporation, H2 2015
Multiple Sclerosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Multiple Sclerosis - Pipeline by Cognosci, Inc., H2 2015
Multiple Sclerosis - Pipeline by Commence Bio, Inc., H2 2015
Multiple Sclerosis - Pipeline by Compugen Ltd., H2 2015
Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015
Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H2 2015
Multiple Sclerosis - Pipeline by Daval International Limited, H2 2015
Multiple Sclerosis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015
Multiple Sclerosis - Pipeline by Digna Biotech, S.L., H2 2015
Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
Multiple Sclerosis - Pipeline by Dong-A Socio Group, H2 2015
Multiple Sclerosis - Pipeline by Effimune SAS, H2 2015
Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H2 2015
Multiple Sclerosis - Pipeline by Endece, LLC, H2 2015
Multiple Sclerosis - Pipeline by Evgen Pharma PLC, H2 2015
Multiple Sclerosis - Pipeline by Evotec AG, H2 2015
Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2015
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2015
Multiple Sclerosis - Pipeline by Genmab A/S, H2 2015
Multiple Sclerosis - Pipeline by Genzyme Corporation, H2 2015
Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2015
Multiple Sclerosis - Pipeline by GliaCure Inc., H2 2015
Multiple Sclerosis - Pipeline by Glialogix, Inc., H2 2015
Multiple Sclerosis - Pipeline by Hansa Medical AB, H2 2015
Multiple Sclerosis - Pipeline by Hanwha Chemical Corporation, H2 2015
Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H2 2015
Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H2 2015

LIST OF FIGURES

Number of Products under Development for Multiple Sclerosis, H2 2015
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4D Pharma Plc
4SC AG
AB Science SA
AbbVie Inc.
Ablynx NV
Acorda Therapeutics, Inc.
Actelion Ltd
Addex Therapeutics Ltd
Aegera Therapeutics Inc.
Aegis Therapeutics, LLC
Affectis Pharmaceuticals AG
AiCuris GmbH & Co. KG
Alkermes Plc
Allozyne, Inc.
Amarna Therapeutics B.V.
Antipodean Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Antitope Limited
Aphios Corporation
Apitope International NV
Arena Pharmaceuticals, Inc.
Argos Therapeutics, Inc.
Array BioPharma Inc.
Arrien Pharmaceuticals, LLC
Artielle ImmunoTherapeutics, Inc.
Athersys, Inc.
Axxam SpA
Baliopharm AG
Bio-Cancer Treatment International Limited
BIOCAD
Biocon Limited
Biogen, Inc.
Biogenomics Limited
Biokine Therapeutics Ltd.
Biomar Microbial Technologies
Bionature E.A. Ltd.
Bioncotech Therapeutics S.L.
Bionovis SA
Bionure Farma, S.L.
Biovista Inc.
Bird Rock Bio, Inc.
Biscayne Pharmaceuticals, Inc.
Bolder Biotechnology, Inc.
BrainStorm Cell Therapeutics Inc.
Bristol-Myers Squibb Company
C4X Discovery Limited
Caladrius Biosciences, Inc.
CASI Pharmaceuticals Inc.
Catalyst Pharmaceutical Partners, Inc.
Cell Cure Neurosciences, Ltd.
Cell2B S.A.
Cellceutix Corporation
Chong Kun Dang Pharmaceutical Corp.
Cognosci, Inc.
Commence Bio, Inc.
Compugen Ltd.
Connexios Life Sciences Pvt. Ltd.
Critical Outcome Technologies Inc.
Daval International Limited
Deltanoid Pharmaceuticals Inc.
Digna Biotech, S.L.
Dimerix Bioscience Pty Ltd
Dong-A Socio Group
Effimune SAS
Eisai Co., Ltd.
Endece, LLC
Evgen Pharma PLC
Evotec AG
F. Hoffmann-La Roche Ltd.
Forward Pharma A/S
Genervon Biopharmaceuticals, LLC
GeNeuro SA
Genmab A/S
Genzyme Corporation
GlaxoSmithKline Plc
GliaCure Inc.
Glialogix, Inc.
Hansa Medical AB
Hanwha Chemical Corporation
Harbor Therapeutics, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
Iltoo Pharma
Immune Response BioPharma, Inc.
ImmuNext, Inc.
Inbiopro Solutions Pvt. Ltd.
InDex Pharmaceuticals AB
Innate Immunotherapeutics Ltd
Inovio Pharmaceuticals, Inc.
InteKrin Therapeutics, Inc.
Invion Limited
Io Therapeutics, Inc.
Jyant Technologies, Inc.
Kadimastem Ltd.
Kadmon Corporation, LLC
KAHR medical Ltd.
KaloBios Pharmaceuticals, Inc.
Kareus Therapeutics, SA
Karo Bio AB
Karyopharm Therapeutics, Inc.
Kineta, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lanthio Pharma B.V.
Lead Discovery Center GmbH
Lipocure Ltd.
Longevity Biotech, Inc
MacroGenics, Inc.
MAKScientific, LLC
Mapi Pharma Ltd.
MedAnnex Ltd
MedDay
MedImmune, LLC
Meiji Seika Pharma Co., Ltd.
Merck KGaA
Meta-IQ ApS
Mitsubishi Tanabe Pharma Corporation
MSM Protein Technologies, Inc.
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
Neurotec Pharma SL
New World Laboratories, Inc.
Novartis AG
NovImmune SA
Nuevolution A/S
Ocata Therapeutics, Inc.
Octapharma AG
Omeros Corporation
OncoImmune, Inc.
Opexa Therapeutics, Inc.
OPKO Health, Inc.
Padlock Therapeutics, Inc.
Peptinov SAS
Pfenex Inc.
Pfizer Inc.
PharmatrophiX, Inc.
Plexxikon Inc.
ProNoxis AB
Provid Pharmaceuticals, Inc.
Q Therapeutics, Inc.
ReceptoPharm, Inc.
Receptos, Inc.
RedHill Biopharma Ltd.
RegeneRx Biopharmaceuticals, Inc.
Regenesance BV
Resverlogix Corp.
ReveraGen BioPharma, Inc.
Rigel Pharmaceuticals, Inc.
SanBio, Inc.
Sanofi
Santhera Pharmaceuticals Holding AG
Sareum Holdings Plc
SK Biopharmaceuticals Co., Ltd.
Sorrento Therapeutics, Inc.
Synthetic Biologics, Inc.
Synthon Holdings BV
Targazyme, Inc.
Teva Pharmaceutical Industries Limited
Therapix Biosciences Ltd
TikoMed AB
Toleranzia AB
Tolero Pharmaceuticals, Inc.
TxCell SA
Upsher-Smith Laboratories, Inc.
Vaccinex, Inc.
Vakzine Projekt Management GmbH
Vertex Pharmaceuticals Incorporated
Vicore Pharma AB
Virogenomics, Inc.
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Xenetic Biosciences plc
XL-protein GmbH
Yungjin Pharm. Co., Ltd.
Zydus Cadila Healthcare Limited
Skip to top


Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 509 pages

Ask Your Question

Multiple Sclerosis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: